Literature DB >> 33512957

18F-FDG PET/CT Monitoring of Response to Programmed Death Protein 1 Blockade in Metastatic Basal Cell Carcinoma.

Hossein Jadvar1, Gino K In2.   

Abstract

ABSTRACT: A 73-year-old woman with history of metastatic basal cell carcinoma presented with a large spinal mass demonstrating a high mutational burden of 111 mutations/Mb. She underwent T12 corpectomy and T10-L3 posterior spinal fusion followed by adjuvant radiation. After 2 years of surveillance, FDG PET/CT and a contrast-enhanced MRI revealed recurrence, prompting salvage therapy with the hedgehog signaling pathway inhibitor, sonidegib, which only transiently stabilized the disease. An off-label treatment with the programmed death protein 1 inhibitor, pembrolizumab, was initiated. Serial FDG PET/CT showed gradual decline in tumor metabolism over the next 12 months, leading to complete metabolic response.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33512957      PMCID： PMC8243770          DOI： 10.1097/RLU.0000000000003528

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   10.782


  7 in total

Review 1.  Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics.

Authors:  M Nikanjam; P R Cohen; S Kato; J K Sicklick; R Kurzrock
Journal:  Ann Oncol       Date:  2018-11-01       Impact factor: 32.976

Review 2.  Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.

Authors:  Ketty Peris; Maria Concetta Fargnoli; Claus Garbe; Roland Kaufmann; Lars Bastholt; Nicole Basset Seguin; Veronique Bataille; Veronique Del Marmol; Reinhard Dummer; Catherine A Harwood; Axel Hauschild; Christoph Höller; Merete Haedersdal; Josep Malvehy; Mark R Middleton; Colin A Morton; Eduardo Nagore; Alexander J Stratigos; Rolf-Markus Szeimies; Luca Tagliaferri; Myrto Trakatelli; Iris Zalaudek; Alexander Eggermont; Jean Jacques Grob
Journal:  Eur J Cancer       Date:  2019-07-06       Impact factor: 9.162

3.  Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.

Authors:  Julia Chang; Gefei A Zhu; Christine Cheung; Shufeng Li; Jinah Kim; Anne Lynn S Chang
Journal:  JAMA Dermatol       Date:  2017-04-01       Impact factor: 10.282

4.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Authors:  Aleksandar Sekulic; Michael R Migden; Anthony E Oro; Luc Dirix; Karl D Lewis; John D Hainsworth; James A Solomon; Simon Yoo; Sarah T Arron; Philip A Friedlander; Ellen Marmur; Charles M Rudin; Anne Lynn S Chang; Jennifer A Low; Howard M Mackey; Robert L Yauch; Richard A Graham; Josina C Reddy; Axel Hauschild
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

5.  Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.

Authors:  Evan J Lipson; Mohammed T Lilo; Aleksandra Ogurtsova; Jessica Esandrio; Haiying Xu; Patricia Brothers; Megan Schollenberger; William H Sharfman; Janis M Taube
Journal:  J Immunother Cancer       Date:  2017-03-21       Impact factor: 13.751

6.  18-FDG PET/CT assessment of basal cell carcinoma with vismodegib.

Authors:  Curtis A Thacker; Glen J Weiss; Raoul Tibes; Lisa Blaydorn; Molly Downhour; Erica White; Jason Baldwin; Daniel D Hoff; Ronald L Korn
Journal:  Cancer Med       Date:  2012-09-17       Impact factor: 4.452

7.  Metastatic Basal cell carcinoma: a biological continuum of Basal cell carcinoma?

Authors:  Karaninder S Mehta; Vikram K Mahajan; Pushpinder S Chauhan; Anju Lath Sharma; Vikas Sharma; C Abhinav; Gayatri Khatri; Neel Prabha; Saurabh Sharma; Muninder Negi
Journal:  Case Rep Dermatol Med       Date:  2012-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.